CJC1295 no DAC + Ipamorelin +GHRP2 - 2mg+2mg+2mg

In clinical studies of patients, GHRP-2 (growth hormone-releasing peptide-2) was used as a stimulation test. In one study, a peak cortisol level below 12 μg/dL in the GHRP-2 stimulation test was specific to hypothalamic secondary adrenal insufficiency among patients with normal cortisol responses to CRH. GHRP2 was one of several tests, along with cosyntropin stimulation, CRH tests, and/or insulin tolerance tests, performed on 36 patients with hypothalamic-pituitary disorder. In patients with pituitary adenomas, GHRP-2 was used as a growth hormone-releasing stimulus in stimulation testing.

In animal studies, ipamorelin is described as a peripherally restricted ghrelin mimetic and a selective ghrelin receptor agonist. In rats, ipamorelin was given intravenously to study visceral and somatic nociception. In animals, the anti-nociceptive effects of ipamorelin and HM01 were blocked by the ghrelin receptor antagonist H0900, indicating a ghrelin receptor-mediated mechanism. In the animal study, the authors suggest that this peripherally restricted ghrelin mimetic may offer a novel approach for treating acute visceral and somatic pain.

GHRP 2, also called GHRP2, acts through the GH secretagogue receptor (GHSR) in the hypothalamus, where ghrelin is a natural ligand. The source states that GHRP2 stimulates the hypothalamic-pituitary-adrenal axis through this receptor. Because it acts as a powerful stimulus for GH secretion, the cut-off peak GH level used in the GHRP2 loading test is higher than in other GH tests.

The provided facts do not mention FDA approval for ipamorelin. A review describes ipamorelin, a growth hormone axis secretagogue, as investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions. The same review's conclusion calls peptides such as ipamorelin experimental substances with poorly defined long-term risks. Growth hormone releasing peptides, the class ipamorelin belongs to, are listed on the World Anti-Doping Agency Prohibited List.

A liquid chromatography-tandem mass spectrometry procedure was developed to extract GHRP-2 and its main metabolite, AA-3, from dried blood spots and detect them. In authentic post-administration specimens analyzed with this dried blood spot method, GHRP-2 was successfully detected. GHRP-2 was chosen as a representative of the growth hormone-releasing peptides family to provide evidence that dried blood spots are suitable for detecting this group of substances in sport testing. In the in vitro analysis, the limit of detection for GHRP-2 in dried blood spot analysis was established at 50 pg/ml.

A review describes Ipamorelin, a growth hormone axis secretagogue, as investigational, with an uncertain safety profile and product quality concerns. The same review concludes that peptides such as Ipamorelin remain experimental substances with poorly defined long-term risks, and that their use should be considered high-risk until longitudinal data are available. The review also notes that the largely unregulated supply chain for peptides such as Ipamorelin means products are often mislabeled or contaminated.

According to the reported analysis, seized powders were identified by LC-HRMS and comparison with reference standards as analogs of GHRP-2 (Pralmorelin). The same powders were also identified as analogs of GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29). The study describes these compounds, including GHRP-2 (Pralmorelin), as growth hormone secretagogues that can be used as performance-enhancing substances in sports.

In a fish study, ipamorelin (IPA) at 5 or 30 µg significantly elevated serum luteinizing hormone (LH) and 11-ketotestosterone (11-KT) compared with controls. The available findings concern 11-ketotestosterone, so they do not directly show a rise in testosterone. Fish treated with 30 µg of IPA also showed a significant elevation in androgen receptor protein expression.

In a human observational study, the GHRP-2 test showed a sensitivity of 64% and a specificity of 79% for diagnosing adrenocortical insufficiency, relative to the insulin tolerance test. Across the whole cohort, the authors judged the GHRP-2 test not suitable for clinical use because of these values. A human observational analysis of male patients without functional adenoma (n = 104) reported a sensitivity of 95% and a specificity of 85% for the GHRP-2 test.

In ferrets, ipamorelin was given intraperitoneally at 1-3 mg/kg 30 s before cisplatin (5 mg/kg, i.p.), with subsequent doses every 24 h, and behaviour was recorded for up to 72 h. In these ferret experiments, intraperitoneally administered ipamorelin had no effect on cisplatin-induced acute or delayed emesis. Ipamorelin inhibited cisplatin-induced weight loss on the last day of the delayed phase (48-72 h) by approximately 24 % in ferrets. The authors concluded that intraperitoneally administered ipamorelin had beneficial effects in alleviating cisplatin-induced weight loss during the delayed phase in ferrets.